NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal

Agreement could cost NHS an extra £3bn a year, industry sources estimate

The Guardian
NHS to pay 25% more for innovative drugs after UK–US zero-tariff deal

Agreement could cost NHS an extra £3bn a year, industry sources estimate

The Guardian
Judge to approve $7bn settlement with OxyContin maker that requires Sackler family members to pay victims https://www.theguardian.com/us-news/2025/nov/14/oxycontin-purdue-pharma-settlement #Pharmaceuticalsindustry #USjusticesystem #Business #Law(US) #USnews
Judge to approve $7bn settlement with OxyContin maker that requires Sackler family members to pay victims

Deal would also require multibillionaire family to give up ownership of the Connecticut-based firm

The Guardian
Antidepressants are trendy. That’s a double-edged sword

It’s great the taboo is fading. But as TikTok influencers tout them, it’s a slippery slope to the memeification of disorders

The Guardian
Top FDA official quits amid inquiry into ‘serious concerns’ over his conduct

Lawsuit claims George Tidmarsh, head of FDA drug center, waged personal vendetta against pharmaceutical executive

The Guardian
‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

The Guardian
Wegovy maker Novo Nordisk’s chair and six other board members step down

Surprise shake-up follows row with majority shareholder, which seeks ‘extensive reconfiguration’

The Guardian
Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public

The Guardian
AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Guardian
NHS could pay 25% more for medicines under plan to end row with drugmakers and Trump

UK ministers preparing to raise payments to end standoff with pharma industry, cited as reason for firms axing British investments

The Guardian